Explore chapters and articles related to this topic
Tacalcitol
Published in Anton C. de Groot, Monographs in Contact Allergy, 2021
Tacalcitol is a vitamin D3 derivative with anti-inflammatory activity that is used in topical pharmaceuticals for the treatment of psoriasis. In such products, both tacalcitol and tacalcitol monohydrate (CAS number 93129-94-3, EC number not available, molecular formula C27H46O4) may be employed (1).
Topical Vitamin D Analogs
Published in Vineet Relhan, Vijay Kumar Garg, Sneha Ghunawat, Khushbu Mahajan, Comprehensive Textbook on Vitiligo, 2020
Tacalcitol side effects are similar to calcitriol. Local skin reactions such as itching, burning, or redness may be experienced. On rare occasions, mild contact dermatitis or worsening of the skin condition may occur. These are usually mild effects and do not last very long. Calcium levels in the blood may increase due to tacalcitol but this cannot currently be substantiated based on the available data, and its frequency is not known [21].
Psoriasis and lichen planus
Published in Ronald Marks, Richard Motley, Common Skin Diseases, 2019
Analogues of vitamin D3 are effective topical treatments; calcipotriol used once or twice daily results in improvement in some 60 per cent of patients after 6 weeks’ treatment. Used alongside medium-potency corticosteroids, the efficacy is increased and the skin irritation decreased. A preparation of calcipotriol formulated together with betamethasone dipropionate is now available as ‘Dovobet®’, and does appear quite effective. Tacalcitol is another vitamin D3 analogue, which, although effective when employed topically, is not as potent as calcipotriol. Apart from skin irritation, there is the concern that a sufficient amount of these D3 analogues will be absorbed to cause hypercalcaemia. Fortunately, this has not proved to be a frequent problem thus far.
Mometasone furoate-loaded aspasomal gel for topical treatment of psoriasis: formulation, optimization, in vitro and in vivo performance
Published in Journal of Dermatological Treatment, 2022
Gajanan Shinde, Pankhita Desai, Santosh Shelke, Rakesh Patel, Ganesh Bangale, Deepak Kulkarni
Psoriasis is a chronic inflammatory skin disease, which may flare up at any cutaneous surface. It is most frequently seen at the exterior surfaces of the sacral areas, scalp, elbow, and knees. The phenotypic appearance of psoriasis is because of hyper proliferation and abnormal differentiation of keratinocytes, inflammatory cell infiltration, and vascular changes (1). Psoriasis may be annoyed by infection, injury, irritation due to cuts, burns, rashes or insect bites and in those patients who already have autoimmune disorders (2). Treatments of psoriasis mainly include topical treatments, systemic treatments and photo therapy (3). Topical treatment is the method of choice due to the limitations of system approach which includes immunosuppression, pregnancy, severe hypertension or metabolic disorder, or severe liver, heart or kidney disease. Wherein the alternative treatments for topical therapies include: keratolytic ointments, tars, dithranol, oil of cade, eosin in 1 or 2% water solution, topical retinoids such as tazarotene, vitamin D analogues such as calcipotriene and tacalcitol, and corticosteroids that are the mainstay of the topical therapy of psoriasis (4). When the body surface is large and the plaques are small and thin phototherapy is the method of choice to treat psoriasis which includes psoralen plus UVA (PUVA), broadband UVB (BB-UVB), and narrowband UVB (NB-UVB) form and excimer laser (5). The main drawback of long-term use of phototherapy is skin cancer like squamous cell carcinoma and malignant melanoma, patient inconvenience and higher running costs (6).
Psoriasis patient preferences for topical drugs: a systematic review
Published in Journal of Dermatological Treatment, 2021
Mathias Tiedemann Svendsen, Steven R. Feldman, Sylvia Naiga Tiedemann, Anne Sofie Stochholm Sørensen, Cecilie Marie Ringgaard Rivas, Klaus Ejner Andersen
Betamethasone valerate mousse was considered more effective than the lotion-based standard treatment for scalp psoriasis (25). Calcipotriol ointment was preferred over dithranol cream by patients with chronic plaque psoriasis (26). High concentration tacalcitol ointment (with single daily application) was preferred over a high-concentration vitamin D3 ointment (27). Due to its high efficacy, nonalcoholic mometasone emulsion was preferred over calcipotriol/betamethasone gel by patients with scalp psoriasis (28). Calcipotriol and betamethasone dipropionate gel was favored in comparison to foam in patients with chronic plaque psoriasis (29). The foam vehicle was preferred, especially by patients with an active flare-up of the disease, since it had an instant soothing effect.
Treatments for inverse psoriasis: a systematic review
Published in Journal of Dermatological Treatment, 2020
Kelly A. Reynolds, Deeti J. Pithadia, Erica B. Lee, Jashin J. Wu
The majority of the treatments assessed in the included studies were topical immunomodulators, including five on tacrolimus (14–18) and two on pimecrolimus (13,22). The second most commonly investigated interventions were topical vitamin D analogs, including calcipotriol (19–22), calcitriol (19), and tacalcitol (21). Two studies assessed the efficacy of mid-potency topical corticosteroids as monotherapy for inverse psoriasis (22,23) and another assessed the combination of a mid-potency corticosteroid with a vitamin D derivative (21). Antiseptic formulations were applied to intertriginous areas in two separate studies (24,25) one of which evaluated a topical antiseptic in combination with a high-potency topical corticosteroid (24). Only one study assessed the specific effects of biologic medications in the treatment of inverse psoriasis lesions (26).